

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Applicant:</b>	<b>HAQUE ET AL.</b>	<b>Examiner:</b>	<b>P.G. SPIVACK</b>
<b>Serial No.:</b>	<b>10/729,276</b>	<b>Group Art Unit:</b>	<b>1614</b>
<b>Filed:</b>	<b>DECEMBER 3, 2003</b>	<b>Docket No.:</b>	<b>12695.13USD2</b>
<b>Confirmation No.:</b>	<b>1586</b>	<b>Customer No.:</b>	<b>23552</b>
<b>Title:</b>	<b>TREATMENT OF CEREBROVASCULAR DISEASE</b>		

---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**(37 C.F.R. § 1.97(c))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Our Deposit Account No. 13-2725 is being charged for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: \_\_\_\_\_

8/4/06



Brian R. Dorn  
Reg. No. 57,395

**23552**

PATENT TRADE MARK OFFICE

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number 12695.13USD2	Application Number 10 729,376
	Applicant: HAQUE ET AL	
	Filing Date: 12/03/2003	Group Art Unit: 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Skochiy et al., "Influence of Membrane Stabilizers and Antioxidant Drugs on Lipid Peroxidation in Cerebral Stroke", <i>UDS</i> , 616.158-915:616891-005 (1993)

**23552**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	